Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. Reply [0.03%]
关于艾万塔马布联合拉泽替尼治疗初治EGFR突变晚期NSqCC的回复
Byoung C Cho,Seema Sethi,Alexander I Spira
Byoung C Cho
Thomas Powles,Matthew D Galsky,Michiel S van der Heijden
Thomas Powles
Shunsuke Koga,Lin Mei
Shunsuke Koga
Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman's Disease [0.03%]
特发性多中心卡斯特尔曼病的肿瘤坏死因子信号通路的作用及靶向治疗研究
Melanie D Mumau,Michael V Gonzalez,Chunyu Ma et al.
Melanie D Mumau et al.
Traveling Companions [0.03%]
同行者
Rachel K Gardner,Daniel A Solomon,Allison S Bloom et al.
Rachel K Gardner et al.
Jonathan P Angel
Jonathan P Angel
Jan-Inge Henter
Jan-Inge Henter
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 [0.03%]
TP53基因插入嵌合抗原受体的CD4⁺T细胞淋巴瘤
Karlo Perica,Nayan Jain,Michael Scordo et al.
Karlo Perica et al.
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of a T-cell lymphoma harboring a lentiviral ...
Alison M Schram,Koichi Goto,Dong-Wan Kim et al.
Alison M Schram et al.
Background: Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 and activation...
Endovascular Treatment for Stroke Due to Occlusion of Medium or Distal Vessels [0.03%]
中远端血管闭塞所致缺血性卒中的血管内治疗
Marios Psychogios,Alex Brehm,Marc Ribo et al.
Marios Psychogios et al.
Background: Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear. ...